Circulating Cancer Stem Cells Expressing EpCAM/CD90 in Hepatocellular Carcinoma: A Pilot Study for Predicting Tumor Recurrence after Living Donor Liver Transplantation

CONCLUSIONS: EpCAM+/CD90+ CTCs can be used preoperatively and 1 day after LDLT as key biological markers in LT candidate selection and post-LDLT management.PMID:34737243 | DOI:10.5009/gnl210162

Source: Gut and Liver - November 5, 2021 Category: Gastroenterology Authors: Hyeo Seong Hwang Jeong Eun Yoo Dai Hoon Han Jin Sub Choi Jae Geun Lee Dong Jin Joo Myoung Soo Kim Soon Il Kim Gi Hong Choi Young Nyun Park Source Type: research